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a b s t r a c t
Primary bone tumors of the jaw are rare. The neoplastic cells in these tumors are the osteoblasts and
osteoclasts. The gnathic bone tumors have also been referred to as borderline. The clinicopathologic
approach towards these bony lesions have been reviewed.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Primary tumors of jaw bone are uncommon [1]. Osteoid-
producing primary bone tumors are encountered in gnathic
apparatus, albeit far less in incidence as compared to their skeletal
counterparts. The neoplasms covered in this review are those in
which the osteoid or bone formation and its progenitor cells are
responsible for the primary pathology [2].
Osteoid is the homogenously eosinophilic organic nonminer-
alised matrix of bone, produced by osteoblasts. The main consti-
tuent, type 1 collagen determines by its alignment whether the
bone is lamellar or woven. The ﬁber arrangement is parallel to one
another in lamellar bone and randomly distributed in woven.
Association of reactive elements like giant cells, hemorrhage and
edematous non-atypical spindle cell stroma is indicative of sec-
ondary repair or fracture callus. In reactive conditions, the bone
formation is focal; progressively maturing and the osteoid islands
are parallel to one another [3].
Bone producing lesions have overlapping histological features.
The term “borderline” has been used throughout the literature for
denoting these overlapping features seen in gnathic bone tumors
[4]. Their distinct clinical and radiographic characterisitcs are used
to provide an accurate diagnosis.
Osseous tumors are deﬁned by the World Health Organization
(WHO) as neoplasms that produce an osseous matrix. These lesions
are divided into benign and malignant on the basis of their biological
behavior [5]. Lesions that are included are the benign tumors—
osteoma, exostosis, osteoid osteoma, osteoblastoma, giant cell tumor
as well as the malignant neoplasm, osteosarcoma [1,6]. Fibro-osseous
lesions like juvenile ossifying ﬁbroma, ossifying ﬁbroma and ﬁbrous
dysplasia are excluded from the discussion as they are essentially
ﬁbrogenic in origin. Computed tomography imaging shows a benign
bone tumor as a well circumscribed lesion with the matrix of the
tumor; characteristics such as cortical breakthrough, bone destruc-
tion, a permeative pattern and associated soft-tissue masses suggest
a malignant bone neoplasm [7].
2. Torus
Exostosis or tori are described simply as bony overgrowths. On
the palate, the exostosis occurs posterior to midline and tends to be
noticeable only by the third decade. In case of the torus mandibu-
laris, the tumor presents itself in the lingual aspect of mandible
opposite the mental foramen. Torus palatinus and torus mandibu-
laris are essentially composed of compact bone with larger speci-
mens associated with cancellous core. Tori are removed only if they
are large enough to interfere with speech or denture stability [2].
3. Benign bone tumors
3.1. Gnathic osteoma
Presenting as a superﬁcial mass or at an endosteal location,
osteoma is the most common benign tumor of the paranasal sinus
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and posterior body of mandible or the condyle. Its incidence is
between 0.014% and 0.43% [8].
Osteomas present as unilateral, well deﬁned mushroom like
radio opaque bone like mass [9]. Compact osteoma is a slow
growing lesion consisting of dense and parallel lamellae of bone
interspersed with marrow spaces. No haversian systems can be
discerned (Figs. 1 and 2). Cancellous osteomas have trabeculae of
bone with intervening marrow spaces and thin cortical bone.
Gardner's syndrome is associated with multiple supernumer-
ary teeth, multiple osteomas, premalignant polyposis coli and
multiple epidermal cysts. These osteomas occur at the alveolar
ridge to medullary spaces to periosteal surfaces of jaws [2].
3.2. Osteochondroma (cartilage capped osteoma)
Primarily occurring in the condylar and coronoid process of the
mandible, osteochondroma presents as mushroom shaped ossiﬁ-
cation beneath a calciﬁed cartilage layer. The microscopic appear-
ance resembles the epiphysis with a cap of hyaline cartilage
overlying bone. The bone is usually of the cancellous variety and
poorly demarcated from the cortex and medulla of the rest of the
jaw bone. Treatment involves complete excision with overlying
periosteum. Sarcomatous transformation in the oro-facial region
has not been documented.
3.3. Osteochondromatosis
Just as in the case of Gardner's syndrome, the face and jaws are
rarely affected. Both osteochondroma and multiple osteochondro-
matosis cease to grow after pubertal growth spurts. Malignant
transformation is rare. The tongue is the most common extra-
skeletal tissue affected [2].
3.4. Gnathic osteoid osteoma and osteoblastoma [OB]
Although more common than osteoblastoma elsewhere in
body, osteoid osteoma is still very rare in the mandible. Osteoid
osteoma of the jaw typically occurs in the age range of 5–24 years.
The association of pain with osteoid osteoma in gnathic sites is a
worrying feature. Since clinicopathologic correlations are impor-
tant in delineating osteoid osteoma from osteoblastoma, it is safest
to characterize all osteoblastic benign tumors of the jaws under
the umbrella term of gnathic osteoblastoma. Even if the lesion is
small it may well represent an early stage of osteoblastoma [10,11].
3.5. Gnathic osteoblastoma
Gnathic osteoblastoma is a rare, expansile, locally aggressive
lesion with a higher frequency in males. Radiographically it usually
presents as a medullary radiolucency with radio-opaque foci of
more than 2 cm in diameter. Sunray appearance or Codman's
triangle has also been reported in up to 25% cases [2]. Also
referred to as giant osteoid osteoma, the osteoblasts are large
and epithelioid in appearance.
Osteoblastomas that occur as bony outgrowths without evi-
dence of central destruction are termed periosteal benign osteo-
blastoma. The reported frequency of osteoblastoma in the jaws
may be artiﬁcially high because tumors are often located in
vicinity of a tooth root. Cementoblastoma is the odontogenic
counterpart of jaw osteoblastoma.
In more cellular variants of OB, osteoid is difﬁcult to detect.
There is a histological continuum between conventional osteo-
blastoma and osteosarcoma with osteoblastoma variants in the
middle [11]. Imaging studies describe OB as an expansile mixed or
sclerotic lesion possessing cortical shell with non-speciﬁc signal
intensity [7].
Osteoblastoma affect the facial region inclusive of jaws in 10%
of cases, more so second and third decades. A mandibular
predilection is noted. If the lesion is adjacent to teeth it may lead
to tooth loosening. Endodontic treatment and extractions may be
attempted for alleviating pain attributed to osteoblastoma.
Benign osteoblastoma are well circumscribed with loosely
arranged polymorphous small uniform cells, mitosis is rare, and
sarcoma giant cells are absent. The tumor is nonpermeative at the
borders [12]. Heavily calciﬁed immature bone, also known as “blue
bone” may be seen (Figs. 3 and 4). Extensive intralesional hemor-
rhage in ﬁbro-vascular spindle cell stroma is identiﬁed. Secondary
aneurysmal bone cyst changes have been seen [13]. Osteoblasts do
not ﬁll the intertrabecular stromal spaces [14]. The word “toxic”
Fig. 1. Compact osteoma with minimal marrow tissue and osteons. Hematoxylin
and eosin stain, 100 .
Fig. 2. Peripheral osteoma in gingival region. Hematoxylin and eosin, 100 .
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osteoblastoma is used when severe systemic symptoms accom-
pany osteoblastoma [5]. Storkel et al. reported a case of psammous
desmo-osteoblastoma in desmal preformed craniofacial bones
[15].
Pseudo-malignant osteoblastoma is used to describe degenera-
tive cytological changes characterized by cells with large degen-
erated nuclei and smudged chromatin mimicking a malignant
tumor.
Multinodular or multifocal osteoblastoma represents osteo-
blastoma with multiple nidi or growth centers within a single
tumor, separated by reactive bone or spindle cell stroma [13].
The term “aggressive” or “epithelioid” or “malignant” osteoblastoma
are rare borderline lesions, non-metastasing but locally aggressive
behavior and with a higher frequency of local recurrence. Osteoblasts
are large and epithelioid with abundant eosinophilic cytoplasm twice
the size of conventional osteoblasts. They arrange themselves in
sheets with little or no intervening osteoid [5,13].
The incidence of aggressive osteoblastoma (AO) is unknown.
The radiographic appearance of AO consists of a circumscribed
lytic defect sometimes surrounded by a sclerotic rim, including
occasional signiﬁcant cortical expansion and destruction. AO tend
to be clinically and radiographically larger (4 cm) than conven-
tional osteoblastoma. Permeation into or entrapment of host bone
is not seen with either variants [16]. In many cases, the aggressive
form has more multinucleated giant cells of the osteoclast type
and more abundant atypical osteoid. It has been reported that the
recurrence rate of aggressive osteoblastoma is 50% and that of
osteoblastoma is 13.6% [17]. They are often mistaken for osteosar-
comas which are histologically differentiated by compact sheets of
malignant osteoblasts blending with osteoid matrix, higher degree
of hyperchromatism, mitotic activity and inﬁltration into sur-
rounding normal tissue [15,18]. A complete conservative excision
generally sufﬁces.
A differential diagnosis to benign osteoblastoma is that of a
solid form of aneurysmal bone cyst that represents 5% of all
aneurysmal bone cyst cases. It is a non-cystic variant with solid
gray white tissue, hemorrhagic foci and abundant ﬁbroblastic and
histiocytic elements with osteoclast like giant cells. Differentiated
areas with osteoid and calciﬁed ﬁbromyxoid tissue complete the
picture [19].
3.6. Gnathic osteosarcoma
Osteosarcoma [OS] is the most common malignant tumor of
bone with the presence of tumor osteoid being directly formed by
tumor cells. Gnathic osteosarcoma [GOS] is uncommon and
different from skeletal osteosarcoma because it exhibits tremen-
dous incessant growth and rare distant metastases [20].
A variable incidence rate of 4–13.3% is reported. Data show GOS
is more prevalent between the ages of 20 and 30 years. The mean
age for OS of the long bones has been reported to be 10.15 years
lesser than GOS [21,22]. 60% of GOS occur in males with studies
indicating the mandible and maxilla to be almost equally affected
[22]. Mandibular tumors arise more frequently in the horizontal
ramus, while the maxillary lesions are commonly discovered in
the alveolar ridge, sinus ﬂoor, and palate [23]. Mandibular neo-
plasms have a better prognosis than maxillary counterparts. A
symphyseal lesion has better prognosis than body, angle or ramus.
5 yr survival rate for gnathic osteosarcoma is 21.5–35% [21].
A typical clinical picture is progressive loosening of teeth,
paresthesia, symmetric widening of periodontal spaces, widening
of inferior dental canal and sunray and Codman's effect at the
periosteal surface. Early lung metastasis may result in respiratory
symptoms. Osteosarcoma of long bones presents as pain during
activity compared to osteosarcoma of jaw bones where swelling is
the commonest ﬁnding. Most patients related the occurrence of
tumor to previous dental treatment, most commonly, dental
extractions [2]. Radiographic presentation is of a sclerotic lesion
with calciﬁed matrix and sunburst periosteal reaction or it may be
mixed or lytic lesion [7]. Osteosarcoma should always be consid-
ered in differentials of exophytic and expansile lesions of the jaws
such as peripheral pyogenic granulomas, ossifying ﬁbroma and
epulis ﬁssuratum [24]. Other unusual clinical presentations may
be increased diastema, buccal or distal repositioning of teeth, and
radio opaque expansion of alveolar crest. Cases of extra skeletal
soft tissue high grade osteosarcoma of tongue have been reported
with prognostic factors being size [45 cm] and regional metas-
tasis [2,26].
Abundant biopsy specimens should be sampled and multiple
expert consultations should be sought [25]. Broders grading is
Fig. 3. Osteoblastoma with large polygonal monomorphic osteoblasts lining
osteoid island in a single line. Vascularity and giant cells noteworthy (450 ).
Fig. 4. Presence of giant cells and blue bone in benign osteoblastoma (450 ).
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done to assess extent of anaplasia. A high grade conventional
central osteosarcoma represents high grade of 3 or 4; parosteal or
low grade (grade 1) central osteosarcoma also exist. If a focus of
anaplasia exists in otherwise grade 1 tumor it is termed as
“dedifferentiated” [20].
Osteosarcoma can be categorized into four major groups:
1) Conventional, high grade osteosarcoma and its histologic sub-
types (75–85%),
2) High grade osteosarcoma that arises in a diseased bone (10%),
3) Intramedullary, well-differentiated (1%),
4) Surface osteosarcoma (5–10%) [27].
GOS has a high microscopic grade in most cases [22]. The
estimated proportion of high grade mandibular OS is 58%. How-
ever, low-grade mandibular osteosarcomas may be underesti-
mated as they are mostly reported as case reports. Estimated
weighted-mean proportions of chondroblastic and osteoblastic
mandibular OS are 37% and 46%, respectively [28].
Central osteosarcoma can be further classiﬁed as high grade
conventional, telengiectatic, small cell, epitheliod, osteoblastoma
like, chondroblastoma like, ﬁbrohistiocytic, giant cell rich, scleros-
ing, clear cell osteosarcoma [1,20]. Central osteosarcoma can be a
low grade lesion. Low grade osteosarcoma has been described as
ﬁbrous dysplasia type, desmoplastic ﬁbroma type, nonossifying
ﬁbroma type, osteoblastoma type, chondromyxoid ﬁbroma type
[2,29].
Surface osteosarcomas are low grade, intermediate type and
high grade. Low grade is referred to as parosteal. Intermediate
variety is referred to as periosteal and high grade is surface or
dedifferentiated parosteal. Parosteal osteosarcomas have a rela-
tively better prognosis than the more centrally located endosteal
medullary lesions. All the same this classiﬁcation is more apt for
the extremities than the gnathic region [2].
The tumor osteoid is dense pink often described as “hard”. It
may show a lace like or sheet like appearance. The osteoid is
curvilinear with small nubs and arborization that appears to be
abortive, lacunae formation. The thickness of the osteoid is highly
variable with the “thinnest” variant referred to as “ﬁligree”.
Osseous matrix has also the predisposition for appositional
deposition upon previously existing normal bone trabeculae
(scaffolding). Tumor cells may be condensed around the osteoid
in palisaded pattern [27].
The tumor cells have a tendency to grow in around vascular
elements giving a “basket-weave” or “cording” pattern [1]. Matrix
formation may not necessarily be the predominant feature with
tumor cells described as pleomorphic, hyper chromatic and
showing mitotic ﬁgures [2]. The term “osteogenic sarcoma with
no predominant growth pattern” is used when histologic sub-
typing is not possible despite generous sampling. Tumor cells are
round to polyhedral, recognized as osteoblasts, ﬁbroblasts and
cartilage cells. Fibroblastic variants have better prognosis than the
osteoblastic type.
In osteoblastic osteosarcoma, the tumor cells are apposed over
the surface of the neoplastic woven bone, exhibiting thin, lace like
osteoid interweaving between neoplastic cells, or broad, large
sheets of coalescing trabeculae [27] (Figs. 5 and 6).
In the jaws, the chondroblastic variant is most common. The
neoplastic chondrocytes are mostly characterized by severe cyto-
logic atypia and reside in lacunar spaces, hyaline matrix or ﬂoat
singly or in cords in myxoid matrix. Myxoid and other forms of
cartilage are also common. The central areas of lesion are richer in
osteoid than the more cellular peripheral zones and have a
“normalizing” inﬂuence on the appearance of the neoplastic cells
[21]. Chemotherapy if given after a biopsy but before deﬁnitive
surgery often causes normalization along with necrosis. This is
referred to as “maturation”.
In sclerosing osteosarcoma, the osteoid is deposited along septa
between adipocytes in the marrow cavity. The surface tension
between marrow adipocytes forces the tumor cells and their
matrix production along the interseptal tissue making it look
thicker than normal.
Telengiectatic osteosarcoma is characterized by bone destruc-
tion, asymmetric expansion and interrupted periosteal reaction. At
higher power the nuclear atypia and high mitotic rate is present
whereas at lower power the blood ﬁlled sinusoids are seen.
Permeation into adjacent marrow tissue or cortical spaces exists.
Osteoid production is sparse. Giant cell rich osteosarcomas like
Fig. 5. Osteosarcoma showing polygonal neoplastic osteoblasts. Hematoxylin and
eosin, 100 .
Fig. 6. Pleomorphic osteoblasts with minimal osteoid; bizarre mitosis and giant
nuclei of osteosarcoma [arrow], hematoxylin and eosin, 450 .
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areas are commonly seen. Cells lining the blood lakes are pleo-
morphic. Telengiectatic osteosarcomas are reminiscent of aneur-
ysmal bone cysts both radiologically and histologically [20].
Aneurysmal bone cysts can easily be interpreted as a giant cell
tumor or an osteoblastoma, and, on occasion, can be mistaken for
osteogenic malignancies [30].
Small cell osteosarcoma combines features of osteosarcoma
and Ewing's sarcoma. Reciprocal translocation between 11 and 22
chromosomes is seen in small cell osteosarcomas. Some authors
believe that small cell osteosarcomas are actually Ewing sarcoma
family tumors with divergent differentiation. The difference arises
when spindle cell foci and osteoid are seen in a round cell rich
picture. This differentiation is crucial as Ewing sarcoma is radio-
sensitive whereas osteosarcomas are radio resistant.
Epithelioid osteosarcoma is an osteosarcoma in which tumor
cells are so poorly differentiated that it is difﬁcult to determine
histologically whether it is sarcoma or carcinoma. Tumor cells are
round or polygonal and they appear cohesive. Post-radiation
osteosarcomas are more often seen demonstrating this pattern.
Crossed polarizers can be employed after picrosirius red staining
to detect these lesions.
Giant cell rich osteosarcomas are difﬁcult to diagnose as they
are confused with those present in giant cell tumor or telengiec-
tatic osteosarcoma [20]. The giant cells need to be distributed
uniformly in solid parts of the tumor to differentiate them from
telengiectatic osteosarcoma. Numerous pleomorphic cells are
associated with telengiectatic osteosarcoma. The giant cell rich
osteosarcomas are seen in skeletally immature persons and
associated with periosteal reaction as compared to giant cell
tumor which occurs in skeletally mature and not associated with
periosteal reaction.
True giant cell tumors may also develop malignancy. A recur-
ring giant cell tumor is termed secondary malignant giant cell
tumor. Sarcomatous tissue identiﬁed in otherwise typical giant cell
tumor is primary malignant giant cell tumor.
Low grade lesions of mandible are rare and represent 2% of
osteosarcomas reported. Low grade osteosarcomas have a predi-
lection for the mandible with longstanding painless swelling as
presentation and minimal mitotic activity but the radiological
ﬁndings usually suggest the diagnosis [29]. Low grade tumor
consists of spindle cells and limited osteoid formation [10].
The differential diagnosis for chondromyxoid ﬁbroma like
variant of osteosarcoma (a low grade variant) is chondroblastic
osteosarcoma. Fibrous dysplasia and desmoplastic ﬁbroma also are
confused with low grade osteosarcomas [5]. Mutational analysis of
GNAS1 reveals positive ﬁndings in ﬁbrous dysplasia but not in
osteosarcoma [10]. Multiple serial sectioning of representative
lesion and obtaining large biopsy tissues in the ﬁrst place prevent
misdiagnosis as ﬁbrous dysplasia, ossifying ﬁbroma.
3.7. Osteoblastoma like and chondroblastomas like osteosarcoma
Osteobalstoma-like osteosarcoma is a low-grade lesion with
radiographic features that can vary from lytic to sclerotic to mixed.
Lesion borders can be well deﬁned, suggesting a benign process, or
can be ill deﬁned and have cortical destruction. Borders of the
tumor show inﬁltration and entrapment of bone. A recent pub-
lication has reported a novel three-way translocation involving
chromosomes 1, 2 and 14 [16]. The dysplastic changes in stromal
cells and osteoblasts are the elements that enable the differentia-
tion of osteoblastoma from low-grade osteosarcoma [17].
Multicentric or multifocal osteosarcomas ﬁrst described by
Silverman in 1936 represent 1–2% of osteosarcomas. They are
synchronous if multiple tumor foci occur within 5 months of
initial presentation or metachronous if multiple tumor foci occur
5 months after initial presentation. They respond poorly to
multimodal therapy. Synchronous multicentric osteosarcoma
affecting the jaw is even rarer with only four cases having been
reported [31].
Another entity found in up to 10% of osteosarcomas is “skip”
metastases. Here a second focus of osteosarcoma is found in the
same bone or in an adjacent bone across a joint.
Well-differentiated osteosarcomas may represent an entirely
different entity, one that is related to an actual osteosarcoma. This
would explain the dilemma evidenced in literature on histological
and radiological diagnosis, differences in response to treatment
and rarity of metastatic disease [32,33].
Biopsy tissues may be obtained via intraoperative procedures
such as aspiration biopsy, imaging assisted core needle biopsies or
open surgical biopsies. In addition to clinicopathologic correlations
teamed with routine staining, there exists the need to conduct
immunohistochemistry, cytogenetic techniques [5]. In the event of
new bone formation, alkaline phosphatase levels are increased.
Hematoxylin and eosin, picrosirius red, ponceau trichrome, and
Masson trichrome staining methods are most frequently used [22].
Osteogenic differentiation of mesenchymal stem cells can be
monitored by using bone morphogenetic proteins (BMPs) and
their downstream mediators, such as the Id proteins. Connective
tissue growth factor (CTGF), as early markers, alkaline phosphatase
and osterix as early/middle markers and osteocalcin and osteo-
pontin as late markers of bone formation may be valuable [27].
Cell Adhesion Molecule1 [CADM1] is a novel osteoblastic adhe-
sion molecule that is expressed transiently during osteoblastic
maturation, and a useful diagnostic marker for osteosarcoma cells
[34]. Recently, it was reported that a combination of MDM2 and
CDK4 by immunohistochemical analysis shows 100% sensitivity and
97.5% speciﬁcity for the diagnosis of low-grade osteosarcoma [35].
Dissemination of osteosarcoma to other organs, especially early
dissemination to the lung, is common, but metastasis to the jaw
has only rarely been reported [36]. Studies comparing jaw osteo-
sarcoma to nonjaw locations conclude that in an osteosarcoma in
old age, treatment is more often conﬁned to surgery or radio-
therapy, and from the age of 60 years onwards chemotherapy is
less often given in malignant diseases. Outcome is less favorable
with increasing age. No signiﬁcant differences in relation to age
were found based on histology of the neoplasm or based on site of
the osteosarcoma (maxilla, mandible, extragnathic sites) [37].
Whereas peripheral OS is regarded as systemic disease at the time
of diagnosis in which 490% of patients develop lung metastases
without multimodality treatment, the vast majority of GOS
patients seem to be curable by complete resection only [38].
Jaw osteosarcomas are characterized by late metastasis but
local invasiveness. Rate of recurrence is 50% with most recurrent
cases being local. Therefore radical excision with clear surgical
margins is advocated. [2] Local failure is the main cause of death in
GOS compared to extragnathic sites [28].
4. Giant cell tumor of jaws [GCT]
GCTs arising in the head and neck region constitute approximately
2% of all GCTs. They are locally aggressive, recurrent and non-
metastasing. Neoplastic giant cell are very rare in jaws. GCT usually
occurs in children and young adults, predominantly females. GCTs are
usually mono-ostotic, although they may occasionally present in a
polyostotic form, when they are usually of a high grade [39]. Radio-
graphic features are of an expansile radiolucent mass crossing the
midline that tends to destroy and remodel the adjacent bone. A
blurred border of the radiolucent area goes in favor of giant cell tumor.
The giant cells represent osteoclast precursors. Numerous uni-
formly dispersed large giant cells with nuclei are seen (Fig. 7).
Hemorrhagic elements are rare. Osteoid is not produced [21,40].
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Due to the similarity of the biological behavior of central giant
cell granulomas [CGCG] of the jaw with that of GCT of long bones,
CGCG of the jaw may be considered as a low grade tumor and the
differences between both may be due to the variations in the
anatomical sites, since the presence of the teeth in addition to the
histological structure of the jaw bone and bone marrow activity,
could inﬂuence the biological behavior of CGCG comparatively.
p53 activity can be used to chart its aggressiveness. The recurrence
rate of CGCG and GCT was 40–45% [41]. Sarcomatous areas may
also develop in giant cell tumor [5].
The primary bone cell derived neoplasms of the gnathic
apparatus show a wide variation from their extragnathic counter-
parts in both diagnosis and treatment approach. The jaw tumors
especially are insidious and often under diagnosed. Repeated
follow ups of all expansile jaw lesions should be the protocol to
counter deceptive clinical presentations.
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